ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1049

Multimorbidity Differences Between Systemic Lupus Erythematosus Patients and Comparators in Different Age Groups: A Large Nationwide US Study

Ali Duarte-Garcia1, Herbert Heien1, Nilay Shah1 and Cynthia Crowson2, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic, Eyota, MN

Meeting: ACR Convergence 2021

Keywords: Aging, Comorbidity, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 8, 2021

Title: Epidemiology & Public Health Poster III: Other Rheumatic & Musculoskeletal Diseases (1022–1060)

Session Type: Poster Session C

Session Time: 8:30AM-10:30AM

Background/Purpose: Patients with Systemic Lupus Erythematosus (SLE) have an increased burden of multimorbidity. Age is strongly associated with accumulation of comorbidities. Patients with SLE may experience multimorbidity at younger ages than their non-SLE controls due to exposure to toxic treatments, disease activity or accelerated aging. We aimed to compare multimorbidity among different age groups of patients with SLE and comparators without SLE.

Methods: We used the OptumLabs Data Warehouse (OLDW), a real-world data asset with de-identified administrative claims to identify cases of SLE and matched comparators. Cases were defined as patients with ≥3 diagnoses of SLE between 1/2006 and 9/2015. Comparators were persons without SLE matched 1:1 on age, sex, race/ethnicity, and enrollment date. Race was classified as White, Black, Asian and Hispanic. Multimorbidity (2 or more comorbidities) was defined using 172 chronic comorbidities from the chronic condition indicator of the clinical classification software (healthcare cost and utilization project). Two or more ICD-9 codes at least 30 days apart were used to define a comorbidity. SLE, cutaneous lupus, and rheumatoid arthritis codes were excluded from the analysis. A secondary analysis was performed including those with 5 or more comorbidities. Conditional logistic regression models were used to estimate odds ratios (OR) with 95% confidence intervals (CI) adjusted for region.

Results: 34,752 cases with SLE and 34,752 matched non-SLE comparators were included. Mean age was 48 (SD 14.2) years, and 90.6% were female for both cohorts. 66.4% of the patients in both cohorts were White, 18.4% Black, 3.4% Asian and 18.4% Hispanic. 1.3% of patients were < 18 years old; 17% 8-34; 21.3% 35-44; 27.1% 45-54; 22.1% 55-64 and 11.2% >65 years. Patients with SLE had more multimorbidity than non-SLE subjects (58.1% vs 26.3%). Multimorbidity increased with age in both cohorts (figure). Multimorbidity differences between SLE and non-SLE were present throughout all the age groups, in general patients with SLE compared to non-SLE had a difference of 27-34% in the prevalence of multimorbidity on all age groups except those age >65 where the difference was 23%. Young patients with SLE had a multimorbidity burden similar to non-SLE comparators who were three decades older (SLE 18-34, 35.95%, non-SLE 55-64, 37.58%). Young patients with SLE were 6-9 times as likely to suffer from multimorbidity compared to matched non-SLE patients in the same age group (table), these differences decreased in older age groups but persisted even in those SLE patients that were >65 (OR 3.5, 95%CI 3.12-3.90). Secondary analysis on patients with 5 or more comorbid conditions showed similar findings (figure and table).

Conclusion: This large nationwide study showed increased occurrence of multimorbidity in SLE versus non-SLE patients, with substantial burden of multimorbidity through all age groups and even persistent during elderhood. Young patients with lupus have a multimorbidity burden of similar to individuals 3 decades older. This study highlights the striking comorbidity burden patients with lupus endure. The effects of multimorbidity on compliance, healthcare burden and outcomes deserve further research.


Disclosures: A. Duarte-Garcia, None; H. Heien, None; N. Shah, None; C. Crowson, None.

To cite this abstract in AMA style:

Duarte-Garcia A, Heien H, Shah N, Crowson C. Multimorbidity Differences Between Systemic Lupus Erythematosus Patients and Comparators in Different Age Groups: A Large Nationwide US Study [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/multimorbidity-differences-between-systemic-lupus-erythematosus-patients-and-comparators-in-different-age-groups-a-large-nationwide-us-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/multimorbidity-differences-between-systemic-lupus-erythematosus-patients-and-comparators-in-different-age-groups-a-large-nationwide-us-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology